title: [Clinical and blood rheologic effects of ticlid in patients with cerebrovascular diseases].
abstract: Clinical efficacy of tiklid in a dose 500 mg/day and its action on platelet vascular hemostasis were evaluated in 24 patients with cerebrovascular diseases. A 15-day tiklid course promoted a regress in some subjective symptoms (headache, vertigo, walking instability, photopsias, etc.), the objective neurological status being unchanged. Tiklid had a positive influence on some rheological parameters and platelet vascular hemostasis. ADP-induced platelet aggregation, blood fibrinogen levels got reduced. The platelets sensitivity to antiaggregation agent PgI2 in vitro arose. Antiaggregation potential of the vascular wall returned to normal in 33% of patients with initially low or inverse response.
authors.forename: Z A
authors.initials: ZA
authors.lastname: Suslina
authors.forename: V G
authors.initials: VG
authors.lastname: Ionova
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Nikitenko
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Maksimova
mesh_terms: D000328:Adult; D001780:Blood Coagulation Tests; D001809:Blood Viscosity / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013988:Ticlopidine / Q000627:therapeutic use*
chemical_list: D013988:Ticlopidine
vernacular_title: Klinicheskie i gemoreologicheskie éffekty tiklida u bol'nykh tserebrovaskuliarnymi zabolevaniiami.